INTRODUCTION AND OBJECTIVES: Clear cell renal cell carcinoma (ccRCC) is characterized by a metabolic feature : an energy production by aerobic glycolysis at the expense of oxydative phosphorylation [1]. Ketogneic diet (KD), which consists of high fat and low carbohydrate intakes, could bring required energy substrates to healthy cells while depriving tumor cells of glucose.
INTRODUCTION AND OBJECTIVES: Treatment of patients with advanced cancers increasingly relies on expensive agents targeting specific molecular or cellular aberrations. Pre-existing and acquired drug resistance typically renders these therapies ineffective, leading to lethal disease. The genome and microenvironment of cancers vary spatially, allowing drug resistance to emerge in any tumor region. To quantify this spatio-functional heterogeneity in response to therapy, we developed an approach based on tumor-implantation into the chorioallantoic membrane of chick embryos (PDXovo).
METHODS: Various cores were obtained from the primary tumor and metastases from patients with metastatic renal cell carcinoma at the time of nephrectomy (N¼6). Each of these cores (5-6 for the primary tumor and 1-3 for metastases) were subdivided into 3 mm sized fragments and were implanted into the chorioallantoic membrane of chick embryos at Day 9 of embryonic development. Two days later, PDXs were treated topically with vehicle or Sunitinib (10 uM final in DMSO) every day until Day 17 of embryonic development. At endpoint (Day 19), all PDXs were submitted to high-frequency ultrasound imaging to quantitate differences in tumor blood perfusion and tumor volume between treatment groups. After imaging, PDXs were individually submitted to total exome sequencing.
RESULTS: We apply this approach to 1548 tumor regions from six renal cell carcinoma patients, achieving a 93.6% engraftment rate. We quantify the spatial heterogeneity in response of these models to sunitinib, an anti-angiogenic therapy, and predict clinical resistance using ultrasound imaging. Combining functional and somatic genomics of the primary tumor and metastases revealed some mutational features associated with sunitinib resistance both at baseline and after treatment.
CONCLUSIONS: These studies establish a rapid and efficient new method of surveying functional tumor heterogeneity in the context of drug resistance. Within 8-10 days of drug challenge, various regions of the primary tumor and metastases can be determined to be resistant or sensitive to targeted therapy, with no outright identifiable molecular signature correlated to drug resistance. This phenotype-based readout was superior to various prognostic scoring criteria systems and point towards PDX based methods to predict de novo drug resistance in patients with metastatic renal cell carcinoma. We have developed an oncolytic measles virus expressing the sodium-iodide symporter (MV-NIS) that has shown early evidence of efficacy in clinical trials against multiple tumor types. In this study, we evaluated infectivity and cell killing of oncolytic MV in patient-derived xenografts from renal Vol. 199, No. 4S, Supplement, Sunday, May 20, 2018 THE JOURNAL OF UROLOGY â e957
